Sign In
Buy VRTX
$441.74
+13.40 (+3.13%)
At Close: Jun 04, 2026
Here's 1 Magnificent Reason to Buy Vertex Pharmaceuticals Stock
10:15am, Wednesday, 03'rd May 2023
It is the only company that has succeeded in treating the underlying causes of cystic fibrosis. The biotech is still working in this area, and given its track record, it's hard to bet against it.
Vertex Pharmaceuticals Just Lost a Potential Rival. Is the Stock a Buy?
02:00pm, Tuesday, 02'nd May 2023
Vertex has generated billions of dollars from its cystic fibrosis treatments. Another big drugmaker aimed to get into the market -- until recently.
Vertex (VRTX) Q1 Earnings Top Estimates, Revenues Up Y/Y
01:43pm, Tuesday, 02'nd May 2023
Vertex Pharmaceuticals' (VRTX) first-quarter 2023 earnings and sales beat estimates. Management reiterates financial guidance for 2023.
2 Supercharged Stocks to Buy for 2023 and Hold for at Least 10 Years
10:00am, Tuesday, 02'nd May 2023
These two healthcare giants have made names for themselves in two very different sectors. Vertex is a powerhouse in the rare disease drug space and also has several promising candidates.
2 Incredible Growth Stocks That Could Turn $20,000 Into $100,000 by 2030
09:09am, Tuesday, 02'nd May 2023
Healthcare and tech aren't slowing down, and intriguing buying opportunities abound in both spaces. Vertex Pharmaceuticals is a profitable healthcare business that is only in the early innings.
Vertex Pharmaceuticals Stock Is an Even Better Buy Now Thanks to AbbVie
05:50am, Tuesday, 02'nd May 2023
AbbVie announced last week that it's shutting down its cystic fibrosis (CF) program. This decision makes Vertex's monopoly in CF even stronger.
Vertex Pharmaceuticals Incorporated (VRTX) Q1 2023 Earnings Call Transcript
09:37pm, Monday, 01'st May 2023
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q1 2023 Earnings Conference Call May 1, 2023 4:30 PM ET Company Participants Susie Lisa - CFA, Senior Vice President, Investor Relations Reshma Kewal
Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Surpass Estimates
07:01pm, Monday, 01'st May 2023
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $3.05 per share, beating the Zacks Consensus Estimate of $2.95 per share. This compares to earnings of $3.52 per share a year ago.
2 Stocks That Could Turn $200,000 Into $1 Million by the Time You Retire
08:43am, Sunday, 30'th Apr 2023
Investing in all market environments is vital to growing your portfolio over time. Upstart is partnering with some pretty impressive names as it builds out its network and long-term growth vision.
3 Unstoppable Stocks to Buy Right Now
06:14am, Saturday, 29'th Apr 2023
AbbVie has several blockbusters to drive growth despite facing sales declines for Humira. Pfizer has much better long-term prospects than might meet the eye.
Strength Seen in Vertex (VRTX): Can Its 5.0% Jump Turn into More Strength?
04:35am, Friday, 28'th Apr 2023
Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road
2 Growth Stocks That Could Double in 5 Years
10:23am, Thursday, 27'th Apr 2023
Vertex Pharmaceuticals will significantly expand its lineup over the next five years. DexCom's continuous glucose monitoring system should have a long growth runway.
3 Biotech Stocks To Watch Today
01:00pm, Tuesday, 25'th Apr 2023
Biotech stocks for your late-April 2023 watchlist.
Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9
08:01am, Tuesday, 25'th Apr 2023
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Bank of America Securities 2023 Health Care Conference on Tuesday, May 9
3 Healthcare Stocks That Could Help Make You a Fortune
02:00pm, Monday, 24'th Apr 2023
Vertex Pharmaceuticals is a leader in its field, bringing in billions of dollars in annual earnings. Teladoc Health has steadily grown revenue, and telemedicine visits, by at least double-digit percen
